Loading
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Previous close
$1.08
+$0.02 · +1.89%
Regular session · ET · Market data may be delayed.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Day range
Current $1.08
52-week range
Current $1.08
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
7
Overpriced
Sentiment
64
Bullish
Risk
72
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Day range
Current $1.08
52-week range
Current $1.08
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 593K USD | 683K USD | 488K USD | 386K USD | 359K USD |
| Gross profit | 593K USD | 683K USD | 488K USD | 386K USD | 359K USD |
| Research and development | 35.33M USD | 36.85M USD | 32.86M USD | 27.11M USD | 17.38M USD |
| Selling, general, and administrative | 14.22M USD | 12.48M USD | 13.04M USD | 13.18M USD | 11.84M USD |
| Operating expenses | 49.55M USD | 49.33M USD | 45.9M USD | 40.29M USD | 29.21M USD |
| Interest income | 3.1M USD | 3.26M USD | 4.07M USD | 1.58M USD | 264K USD |
| Depreciation and amortization | 904K USD | 404K USD | 398K USD | 236K USD | 451K USD |
| Operating income | −48.96M USD | −48.65M USD | −45.41M USD | −39.9M USD | −28.86M USD |
| Net income | −45.85M USD | −45.43M USD | −41.44M USD | −38.7M USD | −28.29M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.00
85.19% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 20, 2019 | 1:6 | — | — |
Stock split | Jun 4, 2018 | 1:12 | — | — |
Stock split | May 30, 2012 | 1:6 | — | — |
Stock split | Jul 27, 2004 | 111:1 | — | — |
Effective Feb 20, 2019
1:6
Effective Jun 4, 2018
1:12
Effective May 30, 2012
1:6
Effective Jul 27, 2004
111:1
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
